RT Journal Article
SR Electronic
T1 Antibody responses to SARS-CoV2 are distinct in children with MIS-C compared to adults with COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.12.20151068
DO 10.1101/2020.07.12.20151068
A1 Weisberg, Stuart P.
A1 Connors, Thomas
A1 Zhu, Yun
A1 Baldwin, Matthew
A1 Lin, Wen-hsuan
A1 Wontakal, Sandeep
A1 Szabo, Peter A.
A1 Wells, Steven B.
A1 Dogra, Pranay
A1 Gray, Joshua
A1 Idzikowski, Emma
A1 Bovier, Francesca T.
A1 Davis-Porada, Julia
A1 Matsumoto, Rei
A1 Li Poon, Maya Meimei
A1 Chait, Michael
A1 Mathieu, Cyrille
A1 Horvat, Branka
A1 Decimo, Didier
A1 Bitan, Zachary C.
A1 La Carpia, Francesca
A1 Ferrara, Stephen A.
A1 Mace, Emily
A1 Milner, Joshua
A1 Moscona, Anne
A1 Hod, Eldad
A1 Porotto, Matteo
A1 Farber, Donna L.
YR 2020
UL http://medrxiv.org/content/early/2020/07/14/2020.07.12.20151068.abstract
AB Clinical manifestations of COVID-19 caused by the novel coronavirus SARS-CoV-2 are associated with age. While children are largely spared from severe respiratory disease, they can present with a SARS-CoV-2-associated multisystem inflammatory syndrome (MIS-C) similar to Kawasaki’s disease. Here, we show distinct antibody (Ab) responses in children with MIS-C compared to adults with severe COVID-19 causing acute respiratory distress syndrome (ARDS), and those who recovered from mild disease. There was a reduced breadth and specificity of anti-SARS-CoV-2-specific antibodies in MIS-C patients compared to the COVID patient groups; MIS-C predominantly generated IgG Abs specific for the Spike (S) protein but not for the nucleocapsid (N) protein, while the COVID-19 cohorts had anti-S IgG, IgM and IgA Abs, as well as anti-N IgG Abs. Moreover, MIS-C patients had reduced neutralizing activity compared to both COVID-19 cohorts, indicating a reduced protective serological response. These results suggest a distinct infection course and immune response in children and adults who develop severe disease, with implications for optimizing treatments based on symptom and age.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by NIH grant AIAI106697 and AI128949 awarded to D.L.F., NIH grants AI121349, NS091263, NS105699, and AI146980 awarded to M.P., and AI114736 awarded to A,M. S.W. is supported by NIH K08DK122130; T.C. is supported by NIH K23 AI141686.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:institutional review board at Columbia University Irving Medical CenterAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe raw data analyzed for this study are available from the authors upon request.